Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology (NASDAQ: CRDF ) has been a biotech of growing interest over the past few years, racing up and down as the fortunes of their PLK1 inhibitor onvansertib have risen and fallen. In particular, thereI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of in ...